← Novartis overview

Novartis vs Eli Lilly and: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Novartis AG (NOVN.SW)

Q3 2026
▼4▲3

Novartis Q3: Approvals and Deals Offset Entresto Plunge and Trial Failures

  • EU approval of Itvisma gene therapy Novartis won European approval for Itvisma, a one-time gene therapy for a rare genetic disorder. This adds a new high-value treatment to its portfolio and supports future revenue growth.

    New approval is a concrete positive catalyst for the stock.

  • FDA full approval of Fabhalta The FDA granted full approval to Fabhalta for a rare kidney disease, removing a prior restriction. This expands the patient population and strengthens Novartis's rare-disease franchise.

    Full approval is a new milestone that can boost sales and sentiment.

  • Q2 earnings beat and return to sales growth Novartis reported second-quarter results that beat expectations, with sales returning to growth. This reassured investors that the core business remains healthy despite patent challenges.

    Earnings beat is a key driver of stock performance in the quarter.

  • Entresto sales plunge 50% on generics Sales of heart drug Entresto fell by half as generic competitors entered the market, costing about $4 billion in annual revenue. This is a major headwind to earnings and growth.

    The loss of a top-selling drug's exclusivity is a significant negative force.

  • Late-stage trial failures for pelacarsen and del-desiran Two experimental drugs, pelacarsen for heart disease and del-desiran for a muscle disorder, failed in late-stage trials. These setbacks reduce the pipeline's potential and raise doubts about future growth.

    Trial failures are a direct negative for pipeline value and investor confidence.

  • Eight CAR-T trials paused after patient deaths Novartis paused eight CAR-T cancer trials following patient deaths. This raises safety concerns, delays potential new treatments, and could hurt its oncology reputation.

    Safety issues can derail a promising area and weigh on the stock.

  • Activist investor demands board overhaul amid high debt Top shareholder Artisan Partners pushed for a board shake-up, citing $39.4 billion in net debt. This adds governance uncertainty and pressure on management to improve performance.

    Activist pressure can lead to strategic changes and short-term volatility.

  • Pipeline wins and acquisitions offset setbacks Novartis advanced remibrutinib, expanded Pluvicto's label, and acquired Myricx Bio and Tourmaline Bio in deals worth billions. These moves show continued investment in innovation despite recent failures.

    These positive pipeline and deal activities are new and balance the negative news.

August 2026
▲3▼1

Pipeline wins and deals offset CAR-T safety setback

  • Remibrutinib MS and hives approvals Remibrutinib won two Phase 3 MS trials and gained FDA approval (Rhapsido) for chronic hives, adding a new revenue stream and strengthening the company's immunology franchise.

    This is a major pipeline win that supports future growth and was not in earlier reports.

  • Pluvicto expanded to earlier prostate cancer Pluvicto was approved for earlier prostate cancer, nearly doubling the number of eligible patients. This expands the market for an existing drug and could significantly boost sales.

    This approval opens a larger patient population and is a new positive catalyst for the stock.

  • Tourmaline Bio acquisition and licensing deals Novartis acquired Tourmaline Bio for $1.4 billion, adding a Phase III cardiovascular drug, and signed licensing deals with Alteogen (up to $3.2 billion) and Abogen (up to $7.8 billion).

    These deals bolster the pipeline and show strategic investment in future growth, a new development this period.

  • CAR-T trial pause and pelacarsen failure Eight CAR-T trials were paused after three patient deaths, raising safety and regulatory risk. Pelacarsen failed its main Phase 3 heart trial goal, removing a growth driver. Shares already trade above many value estimates.

    These setbacks are new negative developments that could pressure the stock and offset positive news.

Latest
▲4

Novartis wins new drug approvals and deals, but pipeline setbacks linger

  • FDA approves Pluvicto for earlier prostate cancer The FDA approved Pluvicto for metastatic hormone-sensitive prostate cancer, nearly doubling the eligible patient population. This expands sales of an already marketed drug and strengthens Novartis's position in radioligand therapy, supporting future revenue growth.

    This is a new regulatory approval that directly expands the market for a key Novartis product.

  • FDA approves Rhapsido for chronic hives The FDA approved Rhapsido (remibrutinib) as the first treatment for symptomatic dermographism, a form of chronic hives. This adds a new approved indication for an oral drug that is also being tested in multiple sclerosis, broadening its potential sales.

    A new FDA approval that opens an additional market for a pipeline drug.

  • Novartis buys Tourmaline Bio for $1.4 billion Novartis agreed to acquire Tourmaline Bio for about $1.4 billion, adding pacibekitug, a Phase III-ready anti-inflammatory drug for heart and kidney diseases. This strengthens its cardiovascular pipeline and shows it is still investing in new science despite recent trial failures.

    A major acquisition that adds a late-stage asset and signals continued pipeline investment.

  • New licensing deal with Abogen worth up to $7.8 billion Novartis signed a licensing and option agreement with China's Abogen Biosciences for its lead mRNA cancer asset, ABO2203, worth up to $7.8 billion including $575 million upfront. This adds a new cancer candidate and shows Novartis can attract outside innovation.

    A large new deal that brings in a new pipeline asset and demonstrates deal-making ability.

September 2026
▼2▲1

Pipeline failures and governance pressure hit Novartis in September

  • Late-stage trial failures Pelacarsen and del-desiran failed late-stage trials, erasing billions in potential revenue and market value, while ALS drug rifonebart was halted. These setbacks hurt sentiment and raised doubts about the pipeline.

    Major negative news that directly impacted investor confidence and valuation.

  • Governance pressure from top shareholder Top shareholder Artisan Partners demanded a board overhaul over dealmaking, with net debt at $39.4 billion and eight shareholders raising concerns. This adds uncertainty about strategy and capital allocation.

    Governance issues can weigh on stock price and investor trust.

  • Pipeline wins and licensing deals Remibrutinib showed best-in-class potential in MS, Cosentyx won EU backing for polymyalgia rheumatica, and Novartis signed licensing deals worth up to $8.1 billion plus acquired Sironax's brain-delivery platform, signaling continued investment in innovation.

    Positive pipeline news and deals support future growth despite recent failures.

▲2▼2

Novartis adds two big pipeline deals; board pressure and CAR-T pause persist

  • Novartis licenses two new pipeline assets in deals worth up to $8.1 billion Novartis signed a radioligand therapy license with BoomRay (up to $900 million) and an mRNA T-cell engager deal with Abogen (up to $7.2 billion). These add new cancer and autoimmune candidates, showing Novartis can still attract outside innovation and giving investors fresh growth hopes after recent trial failures.

    These are the period's only new positive events and directly counter the pipeline-failure narrative that has weighed on the stock.

  • Artisan Partners publicly demands board shake-up over deal oversight Top-20 shareholder Artisan Partners called for a board overhaul after trial failures wiped out $30 billion in market value. Eight shareholders have raised concerns about Novartis' acquisition strategy. This governance pressure keeps uncertainty high and can weigh on the shares until management responds.

    It is a new escalation of shareholder activism that directly questions Novartis' dealmaking and board, a key overhang on the stock.

  • CAR-T trial pause after three patient deaths continues to raise safety concerns Novartis paused eight rap-cel CAR-T trials in autoimmune and neurological diseases after three deaths from a severe immune reaction. The disclosure came only after an analyst noticed the halted trials. This adds regulatory and safety risk, delaying a promising new treatment area and weighing on sentiment.

    It is a new negative safety event that adds to Novartis' pipeline setbacks and can pressure the share price until reviews clear.

  • EU panel backs Cosentyx for polymyalgia rheumatica, expanding a key drug A European Medicines Agency committee recommended approving Cosentyx for polymyalgia rheumatica, a painful inflammatory condition. If the European Commission agrees, it would be the first IL-17A inhibitor cleared for this disease in Europe, adding sales for an already marketed drug and offering a modest lift.

    It is a new regulatory win that expands an existing blockbuster into a new indication, supporting near-term revenue growth.

▲2▼2

Novartis hit by three trial failures; pipeline doubts deepen

  • ALS drug rifonebart halted after mid-stage failure Novartis stopped developing its ALS drug rifonebart after it failed its main and secondary goals in a mid-stage trial of 251 patients. This adds to a string of pipeline setbacks, making investors doubt Novartis's ability to turn research spending into new products and pressuring the shares.

    New pipeline failure that directly adds to negative sentiment and future growth doubts.

  • Novartis buys Sironax brain-delivery platform for $125 million Novartis exercised an option to acquire Sironax's brain-delivery technology for $125 million, gaining a way to get large drugs across the blood-brain barrier. This modestly strengthens its neurology pipeline and shows it is still investing in new science despite recent failures.

    New deal that shows continued pipeline investment and a small positive counterweight.

  • EU panel backs Cosentyx for polymyalgia rheumatica A European Medicines Agency committee recommended approving Cosentyx for polymyalgia rheumatica, a painful inflammatory condition. If the European Commission agrees, it would be the first IL-17A inhibitor cleared for this disease in Europe, expanding sales for an already marketed drug and offering a small lift.

    New regulatory win that broadens an existing product's label and provides a positive offset.

  • Board pressure and $39.4 billion net debt raise capital concerns After the del-desiran failure, top shareholder Artisan Partners demanded a board overhaul, and reports highlighted that Novartis spent over $30 billion on deals, pushing net debt to $39.4 billion. This raises doubts about dealmaking discipline and leaves less room for error, weighing on the stock.

    New details on activist pressure and balance-sheet strain that affect investor confidence.

▼3▲1

Novartis hit by two trial failures, board pressure; MS drug offers hope

  • Pelacarsen heart drug fails, wiping out $6B opportunity Novartis's cholesterol drug pelacarsen failed a final-stage trial, losing a potential $3–6 billion-a-year seller. The news sent shares down 3.3% and removed a key growth driver, making investors question the company's pipeline.

    This is a major pipeline failure that directly hurt the stock and shifts focus to remaining drugs.

  • Muscle-wasting drug del-desiran fails, shares plunge 10–13% The lead asset from Novartis's $12 billion Avidity acquisition failed its pivotal trial, erasing about CHF24–30 billion in market value. This is the third setback in a week and raises doubts about the company's deal-making and pipeline.

    This is the biggest new negative event, causing a record share drop and directly impacting valuation.

  • Top shareholder Artisan Partners demands board shake-up After the record share fall, Artisan Partners publicly urged Novartis to overhaul its board and deal team, citing failed acquisitions. This adds governance and reputational pressure, which can weigh on the stock until management responds.

    This is a new activist investor move that increases uncertainty and could force changes, affecting investor confidence.

  • Remibrutinib beats Sanofi's Aubagio in two late-stage MS trials Novartis's oral MS drug remibrutinib outperformed an older treatment, showing best-in-class potential with no liver-safety issues. Analysts see up to $9 billion in peak sales, offering a bright spot amid recent failures and supporting future growth.

    This is the main positive counterweight, showing pipeline strength and potential to offset losses.

▲2▼2

Novartis pipeline swings: MS win, CAR-T pause, heart drug miss

  • CAR-T trial halt after three deaths Novartis paused eight CAR-T trials for autoimmune and neurological diseases after three patients died from a severe immune reaction. This raises safety and regulatory risk, delays a promising new treatment area, and can weigh on the share price until reviews clear.

    A major safety setback that directly threatens a key pipeline and investor confidence.

  • Remibrutinib wins two Phase 3 MS trials The oral drug remibrutinib beat teriflunomide on relapses and brain lesions in two late-stage MS trials, with no liver-safety worry. This opens a large new market and drove the stock up about 6%, though the shares already trade above many value estimates.

    The period's biggest positive catalyst, with clear efficacy and a large commercial opportunity.

  • Pelacarsen fails main heart trial goal Partner Ionis said Novartis' pelacarsen lowered Lp(a) levels but did not reduce major heart events versus placebo in a Phase 3 trial. This removes a potential growth driver for a common inherited heart risk, hurting sentiment on Novartis' cardiovascular pipeline.

    A late-stage failure that erases a hoped-for new revenue source and dents pipeline credibility.

  • Alteogen deal for subcutaneous versions Novartis signed an option and license deal with Alteogen to turn some intravenous biologics into easier subcutaneous shots, with up to $3.2 billion in potential payments. This could extend the life and convenience of existing products, a modest positive for the pipeline.

    A new partnership that supports future product lifecycles and is not already covered.

July 2026
▲4▼2

Novartis pipeline wins and earnings beat offset Entresto decline

  • EU approval for Itvisma gene therapy Novartis received EU approval for its Itvisma gene therapy, adding a new treatment option and reinforcing its position in advanced therapies. This expands the company's portfolio and offers a potential new revenue stream.

    This is a new regulatory win that supports future growth.

  • FDA full approval for Fabhalta in kidney disease The FDA granted full approval for Fabhalta in kidney disease, transitioning from accelerated approval. This validates the drug's efficacy and allows broader marketing, potentially boosting sales in a new indication.

    This is a new regulatory milestone that could drive revenue.

  • $1.5B Myricx Bio acquisition Novartis acquired Myricx Bio for $1.5 billion, adding a new asset to its pipeline. This strategic move aims to bolster future growth through external innovation.

    This is a new acquisition that expands the pipeline.

  • Q2 earnings beat with sales returning to growth Novartis reported Q2 earnings that beat expectations, with sales returning to growth despite Entresto's decline. This shows resilience and operational execution, reassuring investors about the company's trajectory.

    This is a new financial result that positively surprised the market.

  • Entresto sales plunge 50% on generics Entresto sales fell 50% as generic competition entered the market, resulting in a $4 billion annual revenue hit. This significant loss pressures overall growth and profitability.

    This is a new negative development impacting financials.

  • UBS turns cautious on Novartis relative to peers UBS downgraded its view on Novartis, citing relative underperformance compared to AstraZeneca and Roche. This cautious stance may limit upside and affect investor sentiment.

    This is a new analyst action that could weigh on the stock.

  • High-stakes late-stage trials could add $10B+ but face failure risk Three late-stage trials (pelacarsen, remibrutinib, del-desiran) could add over $10 billion in sales, but Goldman Sachs warns the stock could suffer if at least two fail. This creates meaningful pipeline uncertainty.

    This is a new analyst warning about pipeline risk.

▲2▼1

Novartis wins FDA label expansions, Q2 beat, but Entresto cliff and pipeline risk loom

  • FDA full approval for Fabhalta in kidney disease The FDA granted full approval to Fabhalta for slowing kidney decline in IgA nephropathy, upgrading it from accelerated approval. This expands the market for a first-in-class oral drug and adds a new growth driver, supporting the stock.

    This is a new regulatory win that directly boosts Novartis's revenue outlook.

  • Q2 earnings beat and sales return to growth Novartis beat second-quarter profit and sales estimates, with key brands like Kisqali and Pluvicto growing strongly. Sales returned to growth despite Entresto's 50% decline, reassuring investors and lifting the stock.

    The earnings beat is a new event that shows the company's core business is performing better than expected.

  • Entresto sales plunge 50% on generics Entresto sales fell 50% to $1.18 billion as cheaper generics entered the market, a $4 billion annual revenue hit. This drags on overall growth and pressures the stock, though newer drugs are offsetting some of the loss.

    This is a major negative force that explains why Novartis's growth is muted and why the stock faces a headwind.

  • Pipeline bets face high-stakes trial readouts Novartis is relying on three late-stage trials (pelacarsen, remibrutinib, del-desiran) that could add over $10 billion in sales, but Goldman Sachs warns the stock could suffer if at least two fail. This creates uncertainty around future growth.

    This highlights the key risk and potential reward that will drive the stock's longer-term direction.

▲3▼1

Novartis advances gene therapy and oncology pipeline, but UBS turns cautious

  • EU approval for Itvisma gene therapy Novartis won European Commission approval for Itvisma, a one-time gene replacement therapy for spinal muscular atrophy in patients aged 2 and older. This expands its approved product portfolio in Europe and opens a new revenue stream, supporting the stock.

    This is a concrete regulatory win that directly adds a new approved product and potential sales.

  • Acquisition of Myricx Bio for up to $1.5B Novartis agreed to buy UK biotech Myricx Bio for up to $1.5 billion, gaining a first-in-class antibody-drug conjugate payload platform and two lead assets. This strengthens its oncology pipeline and shows commitment to high-growth areas, a positive for the stock.

    This is a major strategic deal that bolsters the pipeline and signals growth investment.

  • ianalumab positioned in growing markets Novartis' ianalumab is highlighted as a key late-stage candidate in warm autoimmune hemolytic anemia and systemic lupus erythematosus, both large markets with no approved therapies. Phase III results are expected in 2027, offering a potential future growth driver.

    This points to a significant pipeline opportunity that could drive future revenue.

  • UBS cautious on Novartis UBS reiterated an overweight view on European pharma but was more cautious on Novartis, preferring peers like AstraZeneca and Roche. This relative caution may weigh on sentiment and limit the stock's upside compared to sector peers.

    This is a direct analyst opinion that could influence investor perception and relative performance.

Q2 2026
▲3▼1

Novartis pipeline wins offset patent loss in radioligand therapy

  • Patent loss opens door to competitor in key cancer therapy A US court invalidated Novartis patents on its Lutathera radioligand therapy, allowing Curium to launch a competing version. This threatens future sales of a key product, weighing on the stock.

    This is a new negative regulatory event that directly challenges Novartis's radioligand franchise.

  • Positive Phase III data for Rhapsido in chronic inducible urticaria Novartis reported that Rhapsido met primary endpoints in a Phase III trial for chronic inducible urticaria, becoming the first to show efficacy in this condition. This supports a potential new growth driver.

    New clinical success expands the pipeline and boosts confidence in future revenue.

  • Early promise for del-brax in rare muscle disease Novartis's experimental drug del-brax showed promise in an early trial for FSHD, lowering disease markers and muscle damage. If approved, it could be the first disease-modifying treatment, adding a new rare-disease asset.

    New positive trial data for a potential first-in-class therapy supports long-term growth.

  • Oncology deals and market growth outlook Novartis announced two oncology partnerships (Antares, Orionis) worth up to $3.3 billion and a market report projected its radioligand therapy sales to reach $30 billion by 2034. These reinforce its pipeline and leadership in a high-growth area.

    New deals and market forecast highlight Novartis's strategy to offset patent losses and drive future sales.

June 2026
▲3▼1

Novartis pipeline wins offset patent loss in radioligand therapy

  • Patent loss opens door to competitor in key cancer therapy A US court invalidated Novartis patents on its Lutathera radioligand therapy, allowing Curium to launch a competing version. This threatens future sales of a key product, weighing on the stock.

    This is a new negative regulatory event that directly challenges Novartis's radioligand franchise.

  • Positive Phase III data for Rhapsido in chronic inducible urticaria Novartis reported that Rhapsido met primary endpoints in a Phase III trial for chronic inducible urticaria, becoming the first to show efficacy in this condition. This supports a potential new growth driver.

    New clinical success expands the pipeline and boosts confidence in future revenue.

  • Early promise for del-brax in rare muscle disease Novartis's experimental drug del-brax showed promise in an early trial for FSHD, lowering disease markers and muscle damage. If approved, it could be the first disease-modifying treatment, adding a new rare-disease asset.

    New positive trial data for a potential first-in-class therapy supports long-term growth.

  • Oncology deals and market growth outlook Novartis announced two oncology partnerships (Antares, Orionis) worth up to $3.3 billion and a market report projected its radioligand therapy sales to reach $30 billion by 2034. These reinforce its pipeline and leadership in a high-growth area.

    New deals and market forecast highlight Novartis's strategy to offset patent losses and drive future sales.

▲3▼1

Novartis pipeline wins offset patent loss in radioligand therapy

  • Patent loss opens door to competitor in key cancer therapy A US court invalidated Novartis patents on its Lutathera radioligand therapy, allowing Curium to launch a competing version. This threatens future sales of a key product, weighing on the stock.

    This is a new negative regulatory event that directly challenges Novartis's radioligand franchise.

  • Positive Phase III data for Rhapsido in chronic inducible urticaria Novartis reported that Rhapsido met primary endpoints in a Phase III trial for chronic inducible urticaria, becoming the first to show efficacy in this condition. This supports a potential new growth driver.

    New clinical success expands the pipeline and boosts confidence in future revenue.

  • Early promise for del-brax in rare muscle disease Novartis's experimental drug del-brax showed promise in an early trial for FSHD, lowering disease markers and muscle damage. If approved, it could be the first disease-modifying treatment, adding a new rare-disease asset.

    New positive trial data for a potential first-in-class therapy supports long-term growth.

  • Oncology deals and market growth outlook Novartis announced two oncology partnerships (Antares, Orionis) worth up to $3.3 billion and a market report projected its radioligand therapy sales to reach $30 billion by 2034. These reinforce its pipeline and leadership in a high-growth area.

    New deals and market forecast highlight Novartis's strategy to offset patent losses and drive future sales.

Eli Lilly and Company (LLY)

Latest
▲3▼1

Lilly's pipeline and obesity franchise keep winning as competition and legal costs linger

  • Foundayo and Zepbound data widen Lilly's obesity lead New analyses showed higher-dose Zepbound beat high-dose Wegovy on weight loss, and oral Foundayo beat oral semaglutide on weight and blood sugar. Guggenheim raised its Foundayo sales forecasts and price target. These results support future sales and keep Lilly ahead in the obesity market.

    Obesity is Lilly's biggest profit engine, and these data points directly support its pricing power and market share.

  • FDA approvals and pipeline wins broaden Lilly beyond obesity Lilly won FDA approvals for Olumiant in kids with severe alopecia, once-weekly insulin Onswik, and Jaypirca as a first-line leukemia treatment. It also got Breakthrough status for a pancreatic cancer drug and positive eczema trial results. These add new revenue streams and reduce reliance on weight-loss drugs.

    Diversification lowers the risk of depending on one drug class and adds fresh sales growth.

  • Lilly keeps buying and partnering to fuel future growth Lilly signed a deal with InnoCare worth up to $3.35 billion, expanded its Gate Bioscience collaboration past $870 million, and opened AI drug-discovery models to biotech. The CEO said more large acquisitions are coming, funded by obesity-drug cash flow. This builds the pipeline for years ahead.

    These deals show Lilly is reinvesting its profits into new science, which supports long-term growth.

  • Competition and legal setbacks are real counterweights Novo Nordisk data showed its Ozempic had a 6% lower heart-risk than Lilly's Mounjaro, and a jury ordered Lilly to pay about $115 million to Nektar in a contract dispute. A Foghorn cancer collaboration was also halted. These are small versus Lilly's size but show it is not unbeatable.

    It gives the fair picture that Lilly faces genuine competitive and legal headwinds, not just good news.

Q3 2026
▲2▼2

Lilly hits $1T on obesity demand, but competition and coverage risks emerge

  • Lilly becomes first $1 trillion healthcare company Eli Lilly's market value crossed $1 trillion for the first time, driven by Q2 revenue jumping 47.7% to $22.97 billion and raised guidance. Mounjaro and Zepbound alone made up 65% of sales.

    This milestone and the strong financials are the core positive driver of the stock this period.

  • Pipeline advances with acquisitions and new drugs Lilly acquired AtaiBeckley for $3.8 billion, reported Alzheimer's data, won cancer approvals, and its oral GLP-1 Foundayo captured about a third of new US oral GLP-1 patients, showing broad pipeline progress.

    These pipeline and product developments support future growth and are new this period.

  • Novo Nordisk's CagriSema beats Zepbound in head-to-head trial In a direct comparison, Novo's CagriSema helped patients lose 12.4% of their weight versus 9.1% for Zepbound. This competitive threat could pressure Lilly's obesity franchise.

    This is a major new competitive risk that could hurt Lilly's market share and pricing power.

  • Coverage and pipeline setbacks raise concerns About 14% of US employers plan to drop GLP-1 coverage by 2027, and Lilly's retatrutide FDA filing slipped to early 2027. Oral Wegovy also launched in Germany, adding pressure.

    These developments threaten future demand and delay a key pipeline candidate, creating headwinds.

September 2026
▲3▼1

Lilly hits $1T on obesity drug strength, but Novo competition bites

  • Trillion-dollar milestone Eli Lilly became the first healthcare company to reach a $1 trillion market value, powered by its obesity and diabetes drugs. This milestone reflects investors' confidence in Lilly's dominant position in the fast-growing weight-loss market.

    This is the biggest new event of the period and directly explains the stock's rise.

  • Oral pill Foundayo gains traction Lilly's new oral GLP-1 pill, Foundayo, captured about a third of new US oral GLP-1 patients and launched in the UK. It also cut cardiovascular risk in a late-stage trial, expanding its potential use beyond weight loss.

    Shows a new product driving growth and broadening Lilly's market reach.

  • Pipeline and diversification progress Lilly's pipeline advanced with retatrutide showing 20.8% weight loss, plus new FDA approvals for cancer drugs Inluriyo, Verzenio, Onswik, and Jaypirca. The $6.5 billion Houston plant and AtaiBeckley acquisition further diversify beyond obesity.

    Highlights multiple new growth drivers that reduce reliance on a single drug.

  • Novo's CagriSema beats Zepbound Novo Nordisk's CagriSema delivered 12.4% weight loss in a head-to-head trial versus Zepbound's 9.1%. This competitive threat could slow Lilly's obesity market-share gains and pressure future sales growth.

    This is the main counterweight to Lilly's positive news and a real risk to its dominance.

▲5

Lilly's pipeline wins and Foundayo momentum drive growth

  • Foundayo captures one-third of new oral GLP-1 patients Lilly's oral weight-loss pill Foundayo now accounts for about one-third of new patients starting oral GLP-1 medicines, with market share rising weekly. This shows real commercial traction, supporting future sales growth and reinforcing Lilly's obesity leadership.

    This is a new update on Foundayo's market share, directly driving revenue expectations.

  • Lilly raises 2026 revenue guidance to $85-87B Lilly increased its full-year revenue outlook, reflecting strong demand for its obesity and diabetes drugs. Higher guidance signals management confidence and typically lifts investor sentiment, pushing the stock up.

    Guidance raise is a new, concrete financial update that affects valuation.

  • Retatrutide shows 20.8% weight loss in Phase 3 Lilly's experimental triple agonist retatrutide helped patients lose up to 20.8% of body weight in a Phase 3 trial, with strong blood sugar reductions. This bolsters Lilly's pipeline and future growth prospects beyond current drugs.

    New clinical data on a key pipeline asset strengthens long-term growth story.

  • Foundayo cuts cardiovascular risk in large trial In a major Phase 3 trial, Foundayo reduced the risk of heart attacks, strokes, and death compared to insulin in diabetes patients. This could expand the drug's use and strengthen its competitive position, supporting sales.

    New trial results add a cardiovascular benefit, potentially widening Foundayo's label and demand.

  • Jaypirca approved as first-line CLL/SLL treatment The FDA approved Lilly's Jaypirca for previously untreated chronic lymphocytic leukemia, based on a trial showing significantly improved progression-free survival. This expands Lilly's oncology revenue and diversifies beyond obesity.

    New regulatory approval opens a new revenue stream and reduces reliance on GLP-1 drugs.

▲3▼1

Lilly's pipeline and manufacturing expand as competition intensifies

  • FDA approves new breast cancer combo The FDA granted full approval to Lilly's Inluriyo plus Verzenio for ESR1-mutated breast cancer, based on a trial where the combo doubled progression-free survival versus Inluriyo alone. This expands Lilly's oncology offerings and adds a new revenue stream, helping diversify beyond obesity drugs.

    New approval directly boosts Lilly's oncology business and revenue potential.

  • Lilly breaks ground on $6.5B Houston plant Lilly started building a $6.5 billion manufacturing site in Houston to produce active ingredients for its medicines, including the oral obesity drug Foundayo. This is part of a $50 billion U.S. investment to expand capacity and secure supply for future growth.

    Major capital investment supports long-term production capacity and supply chain.

  • Novo's CagriSema beats Zepbound in head-to-head trial In a phase 3 trial, Novo's CagriSema helped patients lose 12.4% of their weight over 60 weeks, compared to 9.1% for Lilly's Zepbound. This suggests a competitive threat in the obesity market, potentially slowing Lilly's market share gains if CagriSema wins approval.

    Direct competitive trial result could pressure Lilly's obesity franchise.

  • FDA approves once-weekly insulin Onswik The FDA approved Lilly's Onswik, a once-weekly basal insulin for type 2 diabetes, which cuts injections from daily to weekly. This strengthens Lilly's diabetes portfolio and offers a more convenient option, potentially capturing market share from daily insulins.

    New product approval expands diabetes franchise and addresses patient convenience.

▲4

Lilly's obesity lead widens as pipeline deals and analyst targets climb

  • Foundayo grabs 30% of new US oral weight-loss patients Lilly's new obesity pill Foundayo has captured over 30% of new US patients starting oral weight-loss medicines, up from almost nothing. Novo's Wegovy pill once held about 90% of that market. This shows Lilly is winning real prescriptions, not just headlines, which supports future sales.

    Concrete evidence that Lilly's newest product is taking market share, a key growth driver.

  • Citi raises Lilly target to Street-high $1,600 Citi lifted its Lilly price target to $1,600, implying about 45% upside, even after the stock fell 8% in a month. The analyst points to Lilly's dominance in obesity prescriptions, Foundayo's prescriber growth, and retatrutide's strong trial results. This boosts investor confidence.

    A major analyst upgrade directly addresses why the stock could move higher despite recent weakness.

  • Lilly completes AtaiBeckley deal for depression drug Lilly closed its acquisition of AtaiBeckley, adding BPL-003, a rapid-acting treatment for depression that resists standard therapy. This expands Lilly's neuroscience pipeline beyond obesity, using its cash to plant seeds for future growth. It reduces reliance on weight-loss drugs.

    Shows Lilly is actively diversifying into new treatment areas, a strategic positive.

  • New data and deals bolster pipeline at EASD and beyond Lilly will present strong trial data for retatrutide, Foundayo, and eloraTZP at a major diabetes conference. It also signed new research deals with QurCan and Twist Bioscience. These moves strengthen Lilly's pipeline and technology, supporting long-term growth even if they don't boost sales immediately.

    Highlights ongoing pipeline progress and partnerships that underpin future revenue.

▲4

Lilly hits $1 trillion as obesity drugs and pipeline deals drive growth

  • Lilly hits $1 trillion market cap on obesity drug strength Lilly crossed $1 trillion in market value, with Q2 revenue up 47.7% and Mounjaro sales up 91%. The obesity franchise and expanded access are powering growth, and analysts see more upside.

    This milestone reflects the scale of Lilly's success and investor confidence, directly answering why the stock is moving.

  • J.P. Morgan raises estimates on obesity drug growth J.P. Morgan lifted 2027 revenue and EPS forecasts, keeping an Overweight rating and $1,400 target. It expects incretin sales to exceed $100 billion by 2030, driven by Zepbound, Mounjaro, and Foundayo.

    Analyst upgrades signal growing confidence in Lilly's long-term growth, a key driver of stock movement.

  • Lilly launches Foundayo in UK, first European market Lilly launched its oral weight-loss pill Foundayo in the UK, the first European market. The pill costs £100-£120 per month, much less than injections, potentially widening access and boosting sales.

    This is a concrete step in expanding Lilly's obesity franchise globally, directly supporting future revenue growth.

  • Lilly builds neuroscience as new growth driver Neuroscience revenue grew 32% to $811 million in H1 2026, led by Kisunla. Acquisitions like AtaiBeckley and Centessa add pipeline assets, diversifying beyond obesity and reducing reliance on GLP-1 drugs.

    This shows Lilly's efforts to create a second growth engine, which could sustain long-term growth and attract investors.

August 2026
▲3▼1

Lilly's Q2 Beat, Pipeline Wins Offset Rising Competition and Coverage Risks

  • Q2 earnings beat and guidance raise Lilly's Q2 revenue jumped 47.7% to $22.97 billion, beating expectations, with Mounjaro and Zepbound making up 65% of sales. Management raised guidance, signaling confidence in continued momentum.

    This is the core new financial result that drove the stock in August.

  • Pipeline and access expansion Lilly widened its lead over Novo Nordisk after CagriSema disappointed. Foundayo won UK approval, cheap access expanded via Amazon and CVS, and new deals in Alzheimer's, oncology, RNA vaccines, and immunology strengthened the pipeline.

    These new developments support future growth and competitive positioning.

  • Label expansions and cost savings Mounjaro gained a heart-risk label, broadening its use, and Zepbound showed cost savings, reinforcing its value proposition. These updates could boost demand and payer acceptance.

    New label and cost data are incremental positives for the franchise.

  • Competition and coverage headwinds Novo Nordisk launched oral Wegovy in Germany and expects a fragmented obesity market. About 14% of US employers plan to drop GLP-1 coverage by 2027, which could slow US sales growth.

    These are new competitive and reimbursement risks that could pressure future sales.

▲3▼1

Lilly's heart-label win and pipeline deals widen its lead

  • FDA expands Mounjaro label to cut heart risks The FDA approved Mounjaro to lower the risk of heart attacks, strokes and heart-related death in high-risk type 2 diabetes patients. This makes the drug useful for more people, supporting sales and pricing power, though it also increases pressure on manufacturing capacity and insurance coverage.

    A new regulatory approval directly expands the market for Lilly's biggest drug.

  • Taltz plus Zepbound shows durable one-year benefit Phase 3b trials showed combining Taltz and Zepbound helped patients with psoriatic disease and obesity achieve clearer skin and more weight loss than Taltz alone after a year. This supports using Lilly drugs together, which could boost sales across both products.

    New clinical data supports broader use of two Lilly drugs together.

  • Lilly buys Merida Biosciences for up to $2.875 billion Lilly agreed to buy Merida Biosciences for up to $2.875 billion, gaining an early-stage immunology drug for Graves' disease and thyroid eye disease. This uses cash from Lilly's obesity franchise to diversify into new treatment areas, though the drug is still years from market.

    A major acquisition shows Lilly using its cash to build new growth beyond weight-loss drugs.

  • Novo launches oral Wegovy in Germany as competition builds Novo Nordisk launched its Wegovy pill in Germany, the EU's largest drug market, and expects pills to take over a third of GLP-1 use by 2030. Lilly's Foundayo pill is in Britain and targeting 40+ markets, so this is a real race for the oral obesity market.

    A direct competitor's launch in a key market threatens Lilly's share of the growing oral GLP-1 market.

▲3▼1

Lilly's GLP-1 lead widens, but employer coverage and pricing risks build

  • Zepbound shown to cut healthcare costs in older adults A real-world study found Zepbound users over 55 had up to 38% lower healthcare costs, with savings reaching $607 per patient per month by 12 months. This evidence could persuade Medicare and insurers to cover obesity drugs, supporting demand.

    This new study directly addresses payer resistance, a key risk, by showing cost savings that could expand coverage and demand.

  • 14% of US employers to drop obesity drug coverage by 2027 A survey shows about 14% of US employers plan to end GLP-1 coverage by 2027 due to rising costs, with the share covering obesity drugs already falling from 72% to 60%. This could reduce Zepbound prescriptions and slow US sales growth.

    This is a new, concrete threat to demand from a major payer group, directly countering the positive coverage narrative.

  • FDA clears Lilly-Roche Alzheimer's blood test The FDA cleared the Elecsys pTau217 blood test, developed with Roche, as the first single-biomarker test to rule in or out Alzheimer's amyloid pathology. This could expand diagnosis and boost the market for Lilly's Alzheimer's drug donanemab.

    This new approval opens a path to wider Alzheimer's diagnosis and treatment, a potential new growth area beyond GLP-1 drugs.

  • Oncology portfolio grows 11%, diversifying beyond GLP-1 Lilly's oncology revenue rose 11% to $4.84 billion in the first half, with newer drugs like Jaypirca up 66% and Inluriyo contributing $110 million. This shows Lilly is building a second growth engine, reducing reliance on obesity drugs.

    This new data highlights a broadening revenue base, which is important for long-term growth and risk reduction.

▲3▼1

Lilly's obesity franchise keeps winning as pipeline and global reach expand

  • UK approves Foundayo for weight loss and diabetes Britain cleared Lilly's once-daily weight-loss pill Foundayo for both obesity and type 2 diabetes, the first European approval. A pill is easier for patients than injections, so it opens a new market and widens Lilly's lead over Novo's rival pill.

    New regulatory approval expands Lilly's addressable market and competitive position.

  • Lilly adds Alzheimer's and ion channel deals Lilly bought rights to an early-stage Alzheimer's drug for $10 million upfront (up to $1 billion more if it works) and teamed up with OmniAb on an ion channel program worth up to $370 million. These small bets refill the pipeline beyond weight-loss drugs.

    New deals diversify Lilly's pipeline and reduce reliance on GLP-1s.

  • Lilly partners on RNA vaccines Lilly signed a research and licensing deal with Amplitude Therapeutics to develop trans-amplifying RNA vaccines for infectious diseases, with options for two more targets. It is an early-stage move into a new treatment area, using Lilly's cash to plant seeds for future growth.

    New collaboration expands Lilly's technology base into vaccines.

  • Novo CEO says obesity market won't be winner-take-all Novo Nordisk's chief said the obesity market will split among many players, like different soda brands, rather than one winner. Novo's oral Wegovy already holds 90% of the oral GLP-1 market. This is a reminder that Lilly's dominance may face limits as competition grows.

    A real counterweight: competition could cap Lilly's long-term market share.

▲4

Lilly's obesity franchise keeps winning as new markets and legal wins add up

  • UK approves Foundayo, first market outside US Britain's regulator cleared Lilly's once-daily weight-loss pill Foundayo, the first approval outside the US. This opens a new market for a pill version of its obesity drug, which could reach patients who dislike injections. It is not yet sold through the NHS while cost regulators review it.

    A brand-new regulatory approval expands Lilly's addressable market beyond the US.

  • Amazon and CVS widen cheap access to Lilly drugs Amazon Pharmacy will offer Lilly's Zepbound pen and Foundayo pill to Medicare patients for $50 a month, and CVS expanded its weight-management program with Lilly, adding app-based access and $29 clinic visits. Easier, cheaper access should lift prescription volumes.

    New distribution deals directly increase how many patients can get Lilly's drugs.

  • Lilly sues sellers of unapproved retatrutide Lilly filed six lawsuits against businesses selling unapproved versions of retatrutide, its experimental obesity drug, and has referred over 200 parties to authorities. This protects the future franchise from unsafe copycats and keeps the market ready for the real drug when approved.

    Legal action defends a key future growth driver from illicit competition.

  • Analysts raise targets on international obesity opportunity BofA lifted its Lilly price target to $1,344 and said overseas obesity sales could eventually beat the US, with most Foundayo peak sales expected abroad. Other banks also raised targets after strong Q2 results. This reflects growing confidence in Lilly's global growth runway.

    Analyst upgrades signal that the market sees more upside from international expansion.

▲4

Lilly's Q2 Beat and Raised Guidance Cement Obesity-Drug Dominance

  • Q2 beat and raised guidance Lilly reported Q2 revenue of $22.97 billion, up 47.7%, and adjusted EPS of $8.38, beating estimates by 27%. Management raised full-year revenue guidance to $85–$87 billion and EPS to $36.25. The stock jumped as much as 7% on the news, reflecting strong demand for its obesity and diabetes drugs.

    This is the core new event that directly answers why LLY is moving right now.

  • Mounjaro and Zepbound sales surge Mounjaro sales jumped 91% to $9.94 billion and Zepbound brought in $4.93 billion, together 65% of total revenue. This shows Lilly's GLP-1 franchise is still growing rapidly, driving the earnings beat and giving confidence that demand remains strong despite competition.

    It explains the fundamental driver behind the beat-and-raise and the stock's move.

  • Novo Nordisk's setback boosts Lilly's competitive edge Novo Nordisk's next-generation obesity drug CagriSema fell short of Lilly's Zepbound in blood sugar control, and Novo guided to a sales decline and cut 9,000 jobs. This strengthens Lilly's position as the clear leader in the obesity market, which supports its pricing power and long-term growth.

    It highlights a key competitive shift that benefits Lilly and is new information.

  • Retatrutide filing planned for early 2027 Lilly plans to file for approval of its next-generation obesity drug retatrutide in early 2027. The drug helped patients lose over 20% of body weight and could also treat sleep apnea and reduce heart risk. Analysts see it as a future growth driver, though it won't contribute revenue until after 2027.

    It is a new pipeline update that reinforces Lilly's long-term growth story.

July 2026
▲2▼1

Lilly hits record on obesity demand, but competition and delays loom

  • Obesity drug demand drives record results Lilly hit record highs as demand for its obesity drugs surged, with revenue jumping 55.5% to $19.8 billion and guidance raised. JPMorgan lifted its price target to $1,400, reflecting strong confidence.

    This is the core positive driver of the stock's record performance in July.

  • Pipeline expansion and strategic investments Lilly expanded its pipeline through the $3.8 billion AtaiBeckley acquisition, positive Alzheimer's data, Canadian approval for Ebglyss, U.S. manufacturing investment, and an AI drug-discovery alliance, supporting future growth.

    These moves strengthen Lilly's long-term growth prospects and diversify its business.

  • Retatrutide shows promise but faces delays Retatrutide showed strong Phase 3 weight loss, but a heart-event imbalance bears watching. Its FDA filing slipped to early 2027 due to manufacturing data gaps, delaying a key growth driver.

    This is a key pipeline update with both positive efficacy and negative regulatory delay.

  • Competition and policy headwinds intensify Germany's rebate reform prompted Lilly to scale back manufacturing there, and Novo Nordisk won EU approval for oral Wegovy, intensifying competition. These pressures could weigh on future sales and margins.

    These are significant risks that emerged in July and could impact Lilly's growth trajectory.

▲4

Lilly's GLP-1 dominance grows as pipeline and supply expand

  • Q1 revenue surges 55.5% on Foundayo launch Lilly's first-quarter revenue jumped 55.5% to $19.8 billion, beating estimates, as new oral GLP-1 Foundayo and strong Mounjaro and Zepbound sales drove growth. Management raised full-year guidance, and an analyst set a $1,365 price target, reinforcing confidence in Lilly's earnings power.

    This shows the core financial engine behind Lilly's stock and why analysts remain bullish.

  • Retatrutide Phase 3 success, FDA filing planned Lilly's next-generation obesity drug retatrutide cut weight by up to 22.6% in Phase 3 trials, with a planned FDA submission in early 2027. This strengthens Lilly's future obesity franchise, though a slight imbalance in serious heart events bears watching.

    It confirms a major future growth driver and addresses the earlier delay, showing the pipeline is back on track.

  • Lilly expands US manufacturing with Resilience Lilly and Resilience are investing $750 million to expand U.S. production of the KwikPen injectable device, creating 400 jobs and boosting supply capacity for diabetes and obesity medicines. This helps ensure Lilly can meet soaring demand and reduces reliance on foreign manufacturing.

    It directly addresses supply constraints that could limit growth and shows Lilly investing in its core business.

  • Lilly joins Illumina's AI drug discovery alliance Lilly became a foundational participant in Illumina's Billion Cell Atlas, gaining access to massive genetic data to speed AI-driven drug discovery. This long-term move could help diversify Lilly's pipeline beyond GLP-1 drugs and keep it at the forefront of biotech innovation.

    It signals a strategic push into next-generation technology that could yield new drugs and reduce reliance on one franchise.

▲1▼1

Lilly buys depression pipeline, but retatrutide filing slips to 2027

  • Lilly to buy AtaiBeckley for up to $3.8B Lilly agreed to pay $2.8 billion upfront, plus up to $1 billion more if milestones are met, for AtaiBeckley and its experimental psychedelic depression treatment. It uses Lilly's cash to add a new growth area beyond weight-loss drugs, though the upfront cost is real.

    This is the period's biggest new deal and shows how Lilly is spending its obesity-drug profits to diversify.

  • Retatrutide approval filing delayed to early 2027 Lilly pushed back its filing for next-generation obesity drug retatrutide because it needs more manufacturing and quality-control data for regulators. The drug still worked well in trials, but the delay means a key future growth driver arrives later than expected.

    This is the main new negative and directly affects Lilly's next big obesity-drug opportunity.

▼2▲1

Lilly's obesity franchise powers growth as it expands into new drug areas

  • Germany's cost reform raises rebates, Lilly to scale back manufacturing Germany passed a law forcing drugmakers to pay higher rebates, aiming to cut €16 billion in health costs. Lilly's CEO said the company will scale back manufacturing plans there, a real headwind for its European business and investment.

    A concrete regulatory setback that could hurt Lilly's sales and expansion in a major market.

  • Lilly acquires AtaiBeckley for up to $3.8 billion Lilly is buying psychedelic drugmaker AtaiBeckley for about $2.8 billion upfront plus up to $1 billion in milestones. This adds a promising treatment for resistant depression to Lilly's pipeline, showing it is using its cash to expand beyond weight-loss drugs.

    A new strategic move that broadens Lilly's pipeline and signals long-term growth ambitions.

  • Novo Nordisk wins EU approval for oral Wegovy Novo Nordisk got EU clearance for the first oral GLP-1 pill for weight management, giving patients a pill option alongside injections. This intensifies competition for Lilly's obesity drugs in Europe, where pill preference could shift market share.

    A direct competitive threat in the key obesity market that could pressure Lilly's growth.

▲3

Lilly rides obesity-drug demand and Medicare expansion to record highs

  • JPMorgan raises price target to $1,400, stock hits record JPMorgan lifted its LLY target from $1,300 to $1,400 and reiterated overweight, citing strong demand for Mounjaro and Zepbound. The stock hit an all-time high above $1,200, with market cap surpassing $1.1 trillion. Analyst expects Q2 earnings to beat consensus.

    This is a new analyst action that directly boosted the stock and reflects confidence in future growth.

  • Lilly presents Alzheimer's data at AAIC 2026 Lilly will present 16 abstracts at the Alzheimer's conference, including new data on its Kisunla treatment and a P-tau217 blood test that could simplify diagnosis. This advances its pipeline beyond obesity, offering another long-term growth driver.

    This is a new pipeline update that shows Lilly's broader research strength beyond weight-loss drugs.

  • Canada backs Lilly's eczema drug Ebglyss Canada's drug agency gave a positive recommendation for Lilly's eczema treatment Ebglyss, which could lead to public reimbursement and wider patient access. Ebglyss is already approved in Canada and other countries, and this expands its reach.

    This is a new regulatory win that broadens Lilly's revenue base beyond obesity and diabetes.

Q2 2026
▲4

Lilly hits record on Medicare obesity coverage and cancer drug progress

  • Medicare opens obesity drugs to millions Starting July 1, Medicare's GLP-1 Bridge program offers Lilly's Zepbound and Foundayo for a flat $50 monthly copay. Up to 20 million seniors may qualify, a huge new market for obesity drugs that previously had no broad coverage.

    This is the biggest new force: a landmark policy change that expands Lilly's customer base and demand.

  • Jaypirca cancer drug advances on two fronts Europe's drug regulator recommended Jaypirca for a type of leukemia, and a Phase 3 trial showed adding it cut disease progression risk by 45%. Lilly will seek wider approvals, strengthening its cancer business beyond weight-loss drugs.

    New clinical and regulatory wins for a key cancer drug diversify Lilly's growth and support the stock.

  • Blockbuster earnings and raised guidance Lilly reported quarterly revenue of $19.8 billion, up 56% from a year ago, with Zepbound and Mounjaro contributing $12.8 billion. It raised full-year guidance to as much as $85 billion in sales and $37 in earnings per share.

    Strong financial results and higher guidance show the business is accelerating, a core reason the stock is moving.

  • Cash-rich Lilly fuels pharma deal spree A wave of drugmaker mergers in 2026, totaling $123 billion, includes Lilly using its GLP-1 cash to make bolt-on acquisitions and a $1.9 billion research deal with China's Abbisko. This helps Lilly fill its pipeline as patents expire.

    Shows how Lilly is deploying its cash to secure future growth, a strategic positive for long-term investors.

June 2026
▲4

Lilly hits record on Medicare obesity coverage and cancer drug progress

  • Medicare opens obesity drugs to millions Starting July 1, Medicare's GLP-1 Bridge program offers Lilly's Zepbound and Foundayo for a flat $50 monthly copay. Up to 20 million seniors may qualify, a huge new market for obesity drugs that previously had no broad coverage.

    This is the biggest new force: a landmark policy change that expands Lilly's customer base and demand.

  • Jaypirca cancer drug advances on two fronts Europe's drug regulator recommended Jaypirca for a type of leukemia, and a Phase 3 trial showed adding it cut disease progression risk by 45%. Lilly will seek wider approvals, strengthening its cancer business beyond weight-loss drugs.

    New clinical and regulatory wins for a key cancer drug diversify Lilly's growth and support the stock.

  • Blockbuster earnings and raised guidance Lilly reported quarterly revenue of $19.8 billion, up 56% from a year ago, with Zepbound and Mounjaro contributing $12.8 billion. It raised full-year guidance to as much as $85 billion in sales and $37 in earnings per share.

    Strong financial results and higher guidance show the business is accelerating, a core reason the stock is moving.

  • Cash-rich Lilly fuels pharma deal spree A wave of drugmaker mergers in 2026, totaling $123 billion, includes Lilly using its GLP-1 cash to make bolt-on acquisitions and a $1.9 billion research deal with China's Abbisko. This helps Lilly fill its pipeline as patents expire.

    Shows how Lilly is deploying its cash to secure future growth, a strategic positive for long-term investors.

▲4

Lilly hits record on Medicare obesity coverage and cancer drug progress

  • Medicare opens obesity drugs to millions Starting July 1, Medicare's GLP-1 Bridge program offers Lilly's Zepbound and Foundayo for a flat $50 monthly copay. Up to 20 million seniors may qualify, a huge new market for obesity drugs that previously had no broad coverage.

    This is the biggest new force: a landmark policy change that expands Lilly's customer base and demand.

  • Jaypirca cancer drug advances on two fronts Europe's drug regulator recommended Jaypirca for a type of leukemia, and a Phase 3 trial showed adding it cut disease progression risk by 45%. Lilly will seek wider approvals, strengthening its cancer business beyond weight-loss drugs.

    New clinical and regulatory wins for a key cancer drug diversify Lilly's growth and support the stock.

  • Blockbuster earnings and raised guidance Lilly reported quarterly revenue of $19.8 billion, up 56% from a year ago, with Zepbound and Mounjaro contributing $12.8 billion. It raised full-year guidance to as much as $85 billion in sales and $37 in earnings per share.

    Strong financial results and higher guidance show the business is accelerating, a core reason the stock is moving.

  • Cash-rich Lilly fuels pharma deal spree A wave of drugmaker mergers in 2026, totaling $123 billion, includes Lilly using its GLP-1 cash to make bolt-on acquisitions and a $1.9 billion research deal with China's Abbisko. This helps Lilly fill its pipeline as patents expire.

    Shows how Lilly is deploying its cash to secure future growth, a strategic positive for long-term investors.